Repligen Co. (NASDAQ:RGEN) Stake Lessened by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. cut its stake in Repligen Co. (NASDAQ:RGEN) by 16.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,567 shares of the biotechnology company’s stock after selling 3,418 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Repligen were worth $2,529,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Amalgamated Bank boosted its holdings in shares of Repligen by 1.0% in the fourth quarter. Amalgamated Bank now owns 25,114 shares of the biotechnology company’s stock valued at $3,615,000 after acquiring an additional 238 shares in the last quarter. Keeler Thomas Management LLC boosted its holdings in shares of Repligen by 68.9% in the fourth quarter. Keeler Thomas Management LLC now owns 8,979 shares of the biotechnology company’s stock valued at $1,294,000 after acquiring an additional 3,662 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Repligen by 8.9% in the fourth quarter. Handelsbanken Fonder AB now owns 14,633 shares of the biotechnology company’s stock valued at $2,106,000 after acquiring an additional 1,200 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 129 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Repligen by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock valued at $83,693,000 after purchasing an additional 14,398 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RGEN has been the subject of several recent research reports. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. increased their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Trading Up 1.7 %

Shares of NASDAQ:RGEN opened at $159.26 on Monday. The firm has a fifty day moving average of $156.17 and a two-hundred day moving average of $148.56. The firm has a market capitalization of $8.92 billion, a P/E ratio of -312.27, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, equities analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.